We aim to evaluate and compare the ability of GLP-1 RAs and SGLT-2 inhibitors to ameliorate the IR of nonalcoholic fatty liver disease (NAFLD) patients.<h4>Data synthesis</h4>Three electronic databases (Medline, Embase, PubMed) were searched from inception until March 2021. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.